A review of the management of patients after percutaneous coronary intervention

International Journal of Clinical Practice

Volumn 60, Issue 5, 2006, Pages 582-589

  Wong, Edmond M L ^a   Wu, E B ^a   Chan, W W M ^a   Yu, C M ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anti coagulation; Chest pain; Complications; Devices; Percutaneous coronary intervention; Platelets; Post procedural management

Indexed keywords

ABCIXIMAB; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CONTRAST MEDIUM; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FLECAINIDE; HEPARIN; PACLITAXEL; PROPAFENONE; RAPAMYCIN; SPIRONOLACTONE; TIROFIBAN; WARFARIN;

ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTERIOVENOUS FISTULA; CARDIAC RESYNCHRONIZATION THERAPY; COMORBIDITY; COMPRESSION THERAPY; CORONARY ARTERY DISEASE; DEFIBRILLATION; DRUG ELUTING STENT; DRUG WITHDRAWAL; ECHOGRAPHY; EXERCISE TEST; FALSE ANEURYSM; FEMORAL ARTERY; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART SCINTISCANNING; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERPERSONAL COMMUNICATION; KIDNEY FAILURE; LEG ISCHEMIA; MEDICAL SPECIALIST; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; PROGNOSIS; RESTENOSIS; RETROPERITONEAL HEMORRHAGE; REVIEW; RISK FACTOR; RISK MANAGEMENT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VASCULAR ACCESS; VASCULAR SURGERY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CHEST PAIN; CORONARY RESTENOSIS; DEFIBRILLATORS, IMPLANTABLE; HUMANS; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; THROMBOCYTOPENIA;

EID: 33646236105     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2006.00824.x     Document Type: Review

References (72)

1. Zijlstra F, de Boer MJ, Hoorntje JC et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993; 328: 680-4.
2. Hochman JS, Sleeper LA, Webb JG et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999; 341: 625-34.
3. Grines CL, Browne KF, Marco J et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993; 328: 673-9.
4. Gibbons RJ, Holmes DR, Reeder GS et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993; 328: 685-91.
5. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997; 336: 1621-8.
6. Schomig A, Kastrati A, Dirschinger J et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med 2000; 343: 385-91.
7. Bach RG, Cannon CP, Weintraub WS et al. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med 2004; 141: 186-95.
8. AHA. Heart Disease and Stroke Statistics - 2005 Update. Dallas, TX: AHA, 2004.
9. Heart stats British Heart Foundation -2004. Available at http://www.bhf.org.uk/news/uploaded/fact_sheet2.pdf (accessed on 22 June 2005).
10. Agostoni P, Biodi-Zoccai GG, de Benedictis ML et al. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures; systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol 2004; 44: 349-56.
11. Muller DW, Shamir KJ, Ellis SG et al. Peripheral vascular complications after conventional and complex percutaneous coronary interventional procedures. Am J Cardiol 1992; 69: 63-8.
12. Archbold RA, Robinson NM, Schilling RJ. Radial artery access for coronary angiography and percutaneous coronary intervention. BMJ 2004; 329: 443-6.
13. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. Arch Intern Med 1990; 150: 1237-42.
14. Davidson C, Hlatky M, Morris K. Cardiovascular and renal toxicity of a nonionic radiocontrast agent after cardiac catheterization. Ann Intern Med 1989; 110: 119-20.
15. Fung J, Szeto C, Chan W et al. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: A randomized trial. Am J Kidney Dis 2004; 43: 801-8.
16. Durham JD, Caputo C, Dokko J, Zaharakis T, Pahlavan M. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002; 62: 2202-7.
17. Goldenberg I, Schechter M, Matetzki S et al. Oral acetylcysteine as an adjunct to saline hydration for prevention of contrast-induced nephropathy following coronary angiography. Eur Heart J 2004; 25: 212-8.
18. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002; 40: 1383-8.
19. Allaqaband S, Tumuluri R, Malik AM et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002; 57: 279-83.
20. Birck R, Krzossok S, Markowetz F, Schnulle P, Van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: Meta-analysis. Lancet 2003; 362: 598-603.
21. Merten GJ, Burgess WP, Gray LV et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 2004; 291: 2328-34.
22. Brieger DB, Mak KH, Marchant KK, Topol EJ. Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998; 31: 1449-59.
23. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
24. EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998; 352: 87-92.
25. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997; 95: 809-13.
26. O'Shea JC, Hafley GE, Greenberg S et al. ESPRIT Investigators (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrelin Therapy trial). Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatideAin coronary stent intervention: The ESPRIT trial: a randomized controlled trial. JAMA 2001; 285: 2468-73.
27. The TARGET Investigators. Comparison of two platelet glycoprotein IIb/ IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888-94.
28. Gibbons RJ, Balady GJ, Beasley JW et al. ACC/AHA guidelines for exercise testing: ExecAtive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (committee on exercise testing). J Am Coll Cardiol 1997; 30: 260-315.
29. Schroeder E, Marchandise B, De Coster P et al. Detection of restenosis after coronary angioplasty for single-vessel disease: How reliable are exercise electrocardiography and scintigraphy in asymptomatic patients? Eur Heart J 1989; 10 (Suppl. G): 18-21.
30. Fioretti PM, Pozzoli MM, Ilmer B et al. Exercise echocardiography versus thallium-201 SPECT for assessing patients before and after PTCA. Eur Heart J 1992; 13: 213-9.
31. Pirelli S, Danzi GB, Alberti A et al. Comparison of usefulness of high-dose dipyridamole echocardiography and exercise electrocardiography for detection of asymptomatic restenosis after angioplasty. Am J Cardiol 1991; 67: 1335-8.
32. Cheitliun MD, Alpert JS, Armstrong WF et al. ACC/AHA guidelines for the clinical application of echocardiography: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. Circulation 1997; 71: 1686-744.
33. Hecht HS, DeBord L, Shaw R et al. Usefulness of supine bicycle stress echocardiography for detection of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1993; 71: 293-6.
34. Ritchie JL, Bateman TM, Bonow RO et al. Guidelines for clinical use of cardiac radionuclide imaging: A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular procedures (Committee on radionuclide Imaging) developed in collaboration with the American Society of Nuclear Cardiology. J Am Coll Cardiol 1995; 25: 521-47.
35. Hecht HS, Shaw RE, Chin HL, Ryan C, Stertzer SH, Myler RK. Silent ischemia after coronary angioplasty: Evaluation of restenosis and extent of ischemia in asymptomatic patients by tomographic thallium-201 exercise imaging and comparison with symptomatic patients. J Am Coll Cardiol 1991; 17: 670-7.
36. Roffi M, Wenaweser P, Meier B et al. Early exercise after coronary stenting is safe. J Am Coll Cardiol 2003; 42: 1569-73.
37. Manyari D, Knudtson M, Kloiber R. Sequential thallium-201 myocardial perfusion studies after successful percutaneous transluminal coronary angioplasty: Delayed resolution of exercise-induced scintigraphic abnormalities. Circulation 1988; 77: 86-95.
38. McFadden EP, Stabile E, Regar E et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-21.
39. The Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502 [Erratum, N Engl J Med 2001; 345: 1506, 1716].
40. Popma JJ, Ohman EM, Weitz J et al. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest 2001; 119: 321-36S.
41. Urban P, Macaya C, Rupprecht HJ et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The Multicenter Aspirin and Ticlopidine Trial After Intracoronary Stenting (MATTIS). Circulation 1998; 98: 2126-32.
42. Schomig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-9.
43. Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665-71.
44. Bertrand ME, Legrand V, Boland J et al. Randomised multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The Full Anticoagulation versus Aspirin and Ticlopidine (FANTASTIC) Study. Circulation 1998; 98: 1597-603.
45. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348: 1329-39.
46. Bhatt DL, Hirsch AT, Topol EJ et al. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. Am Heart J 2000; 140: 67-73.
47. Orford JL, Fasseas P, Berger PB et al. Safety and efficacy of aspirin, clopidogrel and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 2004; 147: 463-7.
48. Van Domburg RT, Foley DP, de Feyter PJ et al. Long-term clinical outcome after coronary balloon angioplasty: Identification of a population at low risk of recurrent events during 17 years of follow-up. Eur Heart J 2001; 22: 934-41.
49. Serruys PW. Arterial Revascularization Therapies Study Part II: Sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. American College of Cardiology 2005 Annual Scientific Session.
50. Serruys PW, Unger F, Sousa JE et al. Comparison of coronary artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344: 1117-97.
51. Uretsky BF, Sheahan RG. Primary prevention of sudden cardiac death in heart failure: Will the solution be shocking? J Am Coll Cardiol 1997; 30: 1589-97.
52. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91. [Erratum appears in N Engl J Med 1992; 327: 1768].
53. Packer M, Bristow MR, Cohn JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U S Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-55.
54. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomized trial. Lancet 1999; 353: 9-13.
55. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
56. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-12.
57. Kuck KH, Cappato R, Siebels J et al. Randomised comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. The Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102: 748-54.
58. Brady GH, Lee KL, Mark DB et al. SCD-HeFT Investigators. Amiodarone or an implantable cardioverter defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-37.
59. Yusuf S, Sleight P, Pogue J et al. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
60. The European Trial On Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in the prevention of cardiovascular events among patients with stable coronary artery disease: Randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.
61. Granger C, McMurray J, Yusuf S et al. The CHARM Investigators. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 2003; 362: 772-6.
62. McMurray J, Ostergren J, Swedberg K et al. The CHARM Investigators. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 2003; 362: 767-71.
63. Pitt B, Zannad F, Remme W et al. Randomised Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-17.
64. Pitt B, Remme W, Zannad F et al. Eplerenone Post-acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.
65. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576-83.
66. Connolly SJ, Gent M, Roberts RS et al. Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297-302.
67. Moss AJ, Hall WJ, Cannon DS et al. Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933-40.
68. Moss AJ, Zareba W, Hall WJ et al. Multicenter Automatic Defibrillator Implantation Trial Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-83.
69. Yu CM, Zhang Q, Fung JW et al. A novel tool to assess systolic asynchrony and identify responders of cardiac resynchronization therapy by tissue synchronization imaging. J Am Coll Cardiol 2005; 45: 677-84.
70. Abraham WT, Fisher WG, Smith AL et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845-53.
71. Cleland JG, Daubert JC, Erdmann E et al. The Cardiac Resynchronization - Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 325: 1539-49.
72. Bristow MR, Saxon LA, Boehmer J et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-50.